

Maruti Suzuki India

Refer to important disclosures at the end of this report

EBITDA below estimates; demand outlook remains intact

- Q1 revenue declined by 1% (3-yr CAGR of 10%) to Rs265bn, in line with estimates. EBITDA fell by 21% qoq (3-yr CAGR of -2%) to Rs19.1bn, 16% below estimates, mainly due to the higher-than-expected impact of commodity inflation. Management expects benefits of lower commodity prices and JPY depreciation to start reflecting in Q2.
- The pending order book is large at ~350,000 units, which includes ~70,000 units for Brezza and ~20,000 units for Grand Vitara. The upcoming launches include the Jimny off-roader, below-4m SUV and a mid-size SUV. We expect an 18% volume CAGR for FY22-24E.
- We reduce FY23E EPS by 4% due to lower other income, while broadly retaining FY24E/25E EPS estimates. We build in a strong revenue CAGR of 24% over FY22-24E, and expect EBITDA margin to expand to 10.7% in FY24E from 6.5% in FY22.
- Our positive view is underpinned by expectations of a cyclical upturn and market share recovery. We reaffirm Buy with a revised TP of Rs10,000 (Rs9,650 earlier), based on 27x core P/E on Sep'24E EPS (Jun'24E EPS earlier) and net cash of Rs1,610/share.

- EBITDA below estimates:** Revenue declined by 1% qoq (3-yr CAGR of 10%) to Rs265bn (est.: Rs263.9bn), broadly in line with our estimates. Volume declined by 4%, while realization grew by 4%. Supply constraints impacted production by 51,000 units. EBITDA declined by 21% to Rs19.1bn (3-yr CAGR of -2%), 16% lower than estimates due to higher-than-expected commodity inflation, discounts and employee costs. EBITDA margin contracted by 190bps to 7.2% (est.: 8.7%). Management expects the benefits of lower commodity prices and JPY depreciation to start reflecting in Q2. Other income declined 81% qoq to Rs885mn due to mark-to-market losses. Overall, adjusted PAT declined by 45% to Rs10.1bn (est.: Rs16.5bn), below estimates on lower operating profit and other income.
- MSIL to gain share on aggressive model action plan:** After the recent launch of the Grand Vitara SUV, upcoming products within the next 18 months include Off-roader (Jimny), mid-size SUV and <4m crossover, which should fill major whitespaces in the company's SUV portfolio. New products have a volume potential of 18,000-25,000 units per month, and we have factored volumes of 74,000/222,000 units in our FY23/24 estimates. In addition, the launch of feature-rich new generation models of Baleno, Celerio, S-presso, Brezza, Alto, Ertiga and XL6 should support volumes. MSIL's market share should increase from 45% in FY22 to 47% in FY24E.
- Maintain Buy** with a TP of Rs10,000, based on 27x core P/E on Sep'24E EPS and net cash of Rs1,610/share. Key downside risks include lower-than-expected demand in key geographies, failure of new products, rise in competitive intensity and adverse movement in commodity/currency rates.

Please see our sector model portfolio (Emkay Alpha Portfolio): [Automobiles & Auto Ancillaries \(Page 8\)](#)

Financial Snapshot (Standalone)

(Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
Revenue	7,03,325	8,82,956	11,73,614	13,62,139	15,13,449
EBITDA	53,453	57,012	1,09,085	1,45,346	1,64,957
EBITDA Margin (%)	7.6	6.5	9.3	10.7	10.9
APAT	42,297	37,663	77,584	1,10,148	1,26,204
EPS (Rs)	140.1	124.7	256.9	364.7	417.9
EPS (% chg)	(25.1)	(11.0)	106.0	42.0	14.6
ROE (%)	8.5	7.1	13.8	17.8	18.3
P/E (x)	61.8	69.4	33.7	23.7	20.7
EV/EBITDA (x)	40.8	38.5	19.8	14.4	12.3
P/BV (x)	5.1	4.8	4.5	4.0	3.6

Source: Company, Emkay Research

CMP	Target Price
Rs 8,658 as of (July 27, 2022)	Rs 10,000 (▲) 12 months
Rating	Upside
BUY (■)	15.5 %

Change in Estimates

EPS Chg FY23E/FY24E (%)	(4.2)/ (0.2)
Target Price change (%)	3.6
Target Period (Months)	12
Previous Reco	BUY

Emkay vs Consensus

	EPS Estimates	
	FY23E	FY24E
Emkay	256.9	364.7
Consensus	243.2	342.6
Mean Consensus TP (12M)	Rs 9,204	

Stock Details

Bloomberg Code	MSIL IN
Face Value (Rs)	5
Shares outstanding (mn)	302
52 Week H/L	9,050 / 6,537
M Cap (Rs bn/USD bn)	2,615 / 32.73
Daily Avg Volume (nos.)	7,32,804
Daily Avg Turnover (US\$ mn)	73.4


Shareholding Pattern Jun '22

Promoters	56.4%
FIIs	21.9%
DIIIs	18.0%
Public and Others	3.7%

Price Performance

(%)	1M	3M	6M	12M
Absolute	2	11	(2)	20
Rel. to Nifty (3)	14	1	13	

Relative price chart



Source: Bloomberg

This report is solely produced by Emkay Global. The following person(s) are responsible for the production of the recommendation:

Raghunandhan N L

raghunandhan.nl@emkayglobal.com
+91 22 6624 2428

Mumuksh Mandlesha


mumuksh.mandlesha@emkayglobal.com
+91 22 6612 1334

Bhargava Perni

bhargava.perni@emkayglobal.com
+91 22 6624 2429


Story in Charts

Exhibit 1: Q1FY23 volumes at 467,931 units; expect robust volume growth at 18% CAGR over FY22-24E




Source: Company, Emkay Research

Exhibit 2: Revenue/unit grew by 4% qoq to Rs566,319




Source: Company, Emkay Research

Exhibit 3: Blended discounts/revenue higher by 20bps to 2.3% but still lower than last year level of 2.8%




Source: Company, Emkay Research

Exhibit 4: Gross profit/unit stood at Rs143,816




Source: Company, Emkay Research

Exhibit 5: EBITDA margin at 7.2%. Expect margins to improve going forward



Source: Company, Emkay Research

Exhibit 6: One-year forward P/E (average at 29x, +1 std at 42x and -1 std at 17x)



Source: Company, Emkay Research

Earnings Call Highlights

- The pending order-book is large at ~350,000 units in the domestic market.
- The recently launched Brezza has received total bookings of 70,000 units. The top variants (Zxi and Zxi+) contributed more than 50% of the bookings.
- The recently unveiled Grand Vitara has pending order bookings of 20,000. Of this, 45% of the bookings are for hybrids.
- Export outlook remains positive. The company is benefiting from leveraging Suzuki's and Toyota's global distribution networks.
- Benefits of lower commodity prices and JPY depreciation are expected to reflect from Q2FY23.
- Marketing costs are expected to increase this year due to new launches.
- The IMT Kharkhoda plant will have a capacity of 250,000 vehicles. This can be expanded further and the commissioning of this plant is expected in 2025. The capex is planned at Rs110bn.
- JPY direct exposure stands at ~3% and indirect exposure was at JPY85bn.

Q1FY23 highlights

- Supply issues led to a production loss of ~51,000 units.
- Commodity inflation impact stood at ~200bps, which was partially offset by price increases (130bps).
- CNG contributed 20% of total sales.
- Blended discounts increased to Rs12,750/unit vs. Rs11,130/unit in Q4FY22 and 13,911 in Q1FY22.
- SMC production stood at 31% of volume.
- Royalty stood at 3.7%. The amount is being paid completely in rupees.
- Export revenue stood at Rs36.4bn vs. Rs35.1bn in Q4FY22.

Exhibit 7: Key assumptions: Revenue CAGR expected at 24% over FY22-24E

Key revenue assumptions	FY20	FY21	FY22	FY23E	FY24E	FY25E	CAGR FY22-24E
Volume (units)							
Domestic Passenger Cars	1,085,646	981,658	954,609	1,183,600	1,247,441	1,309,813	14%
YoY %	(15.6)	(9.6)	(2.8)	24.0	5.4	5.0	
Domestic Utility Vehicles	235,298	245,427	317,331	435,744	572,729	661,562	34%
YoY %	(10.9)	4.3	29.3	37.3	31.4	15.5	
Domestic Vans	118,404	105,081	108,345	134,890	147,030	155,851	16%
YoY %	(33.7)	(11.3)	3.1	24.5	9.0	6.0	
Domestic LCVs	21,778	29,556	34,240	37,963	42,139	45,510	11%
YoY %	(8.8)	35.7	15.8	10.9	11.0	8.0	
Total Domestic	1,461,126	1,361,722	1,414,525	1,792,197	2,009,339	2,172,736	19%
YoY %	(16.7)	(6.8)	3.9	26.7	12.1	8.1	
Exports	102,171	96,139	238,376	268,417	292,574	315,980	11%
YoY %	(6.0)	(5.9)	147.9	12.6	9.0	8.0	
Total	1,563,297	1,457,861	1,652,901	2,060,613	2,301,913	2,488,717	18%
YoY %	(16.1)	(6.7)	13.4	24.7	11.7	8.1	
Realization (Rs/unit)	483,661	482,436	534,186	569,546	591,742	608,124	5%
YoY %	4.7	(0.3)	10.7	6.6	3.9	2.8	
Revenue (Rs mn)	756,106	703,325	882,956	1,173,614	1,362,139	1,513,449	24%
YoY %	(12.1)	(7.0)	25.5	32.9	16.1	11.1	

Source: Company, Emkay Research

Exhibit 8: Changes in estimates

(Rs mn)	FY23E				FY24E				FY25E			
	Earlier	Revised	% Change	% YoY	Earlier	Revised	% Change	% YoY	Earlier	Revised	% Change	% YoY
Volumes (Units)	2,013,854	2,060,613	2.3	24.7	2,298,302	2,301,913	0.2	11.7	2,480,707	2,488,717	0.3	8.1
Revenues	1,137,600	1,173,614	3.2	32.9	1,343,020	1,362,139	1.4	16.1	1,490,185	1,513,449	1.6	11.1
EBITDA	109,483	109,085	(0.4)	91.3	146,095	145,346	(0.5)	33.2	165,324	164,957	(0.2)	13.5
Margin (%)	9.6	9.3	(33) bps	284 bps	10.9	10.7	(21) bps	138 bps	11.1	10.9	(19) bps	23 bps
PAT	80,992	77,584	(4.2)	106.0	110,385	110,148	(0.2)	42.0	126,298	126,204	(0.1)	14.6
EPS (Rs)	268.2	256.9	(4.2)	106.0	365.5	364.7	(0.2)	42.0	418.2	417.9	(0.1)	14.6
Core PAT	61,349	61,641	0.5	180.4	87,232	87,363	0.1	41.7	99,873	100,188	0.3	14.7
Core EPS (Rs)	203.1	204.1	0.5	180.4	288.8	289.3	0.1	41.7	330.7	331.7	0.3	14.7

Source: Company, Emkay Research

Exhibit 9: Actual vs. Estimates (Q1FY23)

(Rs mn)	Actual	Estimates		% Variation		Comment
		Emkay	Consensus	Emkay	Consensus	
Revenues	264,998	263,878	257,782	0.4	2.8	Broadly in line with estimates
EBITDA	19,121	22,886	22,171	(16.5)	(13.8)	Lower than estimates due to higher-than-expected commodity inflation, discounts and employee costs
EBITDA Margin (%)	7.2	8.7	8.6	(146) bps	(139) bps	
Adjusted net profit	10,128	16,454	15,696	(38.4)	(35.5)	Below estimates due to lower operating profit and other income

Source: Bloomberg, Company, Emkay Research

Exhibit 10: Quarterly financial summary

Rs mn	Q1FY22	Q2FY22	Q3FY22	Q4FY22	Q1FY23	YoY (%)	QoQ (%)
Revenue	177,707	205,389	232,460	267,400	264,998	49.1	(0.9)
Expenditure	169,496	196,840	216,870	243,132	245,877	45.1	1.1
as % of sales	95.4	95.8	93.3	90.9	92.8		
Consumption of RM	132,905	155,770	175,031	196,667	197,702	48.8	0.5
as % of sales	74.8	75.8	75.3	73.5	74.6		
Employee Cost	10,643	9,622	9,699	10,258	11,584	8.8	12.9
as % of sales	6.0	4.7	4.2	3.8	4.4		
Other expenditure	25,948	31,448	32,140	36,207	36,591	41.0	1.1
as % of sales	14.6	15.3	13.8	13.5	13.8		
EBITDA	8,211	8,549	15,590	24,268	19,121	132.9	(21.2)
Depreciation	7,432	7,561	6,400	6,472	6,514	(12.4)	0.6
EBIT	779	988	9,190	17,796	12,607	1,518.4	(29.2)
Other Income	5,078	5,227	3,280	4,744	885	(82.6)	(81.3)
Interest	222	225	252	560	274	23.4	(51.1)
PBT	5,635	5,990	12,218	21,980	13,218	134.6	(39.9)
Total Tax	1,227	1,237	2,105	3,591	3,090	151.8	(14.0)
Adjusted PAT	4,408	4,753	10,113	18,389	10,128	129.8	(44.9)
Extra ordinary items	-	-	-	-	-		
Reported PAT	4,408	4,753	10,113	18,389	10,128	129.8	(44.9)
Adjusted EPS	14.6	15.7	33.5	60.9	33.5	129.8	(44.9)

Margins (%)						(bps)	(bps)
EBIDTA	4.6	4.2	6.7	9.1	7.2	259	(186)
EBIT	0.4	0.5	4.0	6.7	4.8	432	(190)
EBT	3.2	2.9	5.3	8.2	5.0	182	(323)
PAT	2.5	2.3	4.4	6.9	3.8	134	(306)
Effective Tax rate	21.8	20.7	17.2	16.3	23.4	160	704

Source: Company, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 08/22/2022 11:31 AM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Key Financials (Standalone)**Income Statement**

Y/E Mar (Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
Revenue	7,03,325	8,82,956	11,73,614	13,62,139	15,13,449
Expenditure	6,49,872	8,25,944	10,64,530	12,16,793	13,48,492
EBITDA	53,453	57,012	1,09,085	1,45,346	1,64,957
Depreciation	30,315	27,865	27,063	29,108	31,552
EBIT	23,138	29,147	82,022	1,16,238	1,33,405
Other Income	29,464	17,935	16,217	22,768	25,738
Interest expenses	1,008	1,259	1,259	1,322	1,388
PBT	51,594	45,823	96,980	1,37,684	1,57,755
Tax	9,297	8,160	19,396	27,537	31,551
Extraordinary Items	0	0	0	0	0
Minority Int./Income from Assoc.	0	0	0	0	0
Reported Net Income	42,297	37,663	77,584	1,10,148	1,26,204
Adjusted PAT	42,297	37,663	77,584	1,10,148	1,26,204

Balance Sheet

Y/E Mar (Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
Equity share capital	1,510	1,510	1,510	1,510	1,510
Reserves & surplus	5,12,158	5,39,350	5,85,901	6,51,989	7,27,712
Net worth	5,13,668	5,40,860	5,87,411	6,53,499	7,29,222
Minority Interest	0	0	0	0	0
Loan Funds	4,888	3,819	5,076	5,892	6,546
Net deferred tax liability	3,847	(2,027)	(2,124)	(2,262)	(2,419)
Total Liabilities	5,22,403	5,42,652	5,90,363	6,57,129	7,33,348
Net block	1,49,570	1,37,173	1,76,904	1,97,796	2,16,244
Investment	4,17,867	4,07,633	4,37,633	5,04,633	5,69,633
Current Assets	1,18,339	1,57,816	2,03,452	2,21,137	2,41,258
Cash & bank balance	30,364	30,362	37,248	28,235	26,928
Other Current Assets	44,477	71,515	95,057	1,10,326	1,22,582
Current liabilities & Provision	1,78,271	1,89,264	2,40,126	2,78,937	3,06,286
Net current assets	(59,932)	(31,448)	(36,675)	(57,800)	(65,028)
Misc. exp	0	0	0	0	0
Total Assets	5,22,403	5,42,652	5,90,363	6,57,129	7,33,348

Cash Flow

Y/E Mar (Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
PBT (Ex-Other income) (NI+Dep)	22,130	27,888	80,763	1,14,916	1,32,017
Other Non-Cash items	0	0	0	0	0
Chg in working cap	43,352	(28,098)	(1,172)	(1,229)	(801)
Operating Cashflow	58,924	(23)	88,791	1,16,759	1,32,748
Capital expenditure	(23,279)	(33,227)	(50,000)	(50,000)	(50,000)
Free Cash Flow	35,645	(33,250)	38,791	66,759	82,748
Investments	(50,363)	29,074	(30,000)	(67,000)	(65,000)
Other Investing Cash Flow	803	2,263	0	0	0
Investing Cashflow	(43,375)	16,045	(63,783)	(94,232)	(89,262)
Equity Capital Raised	0	0	0	0	0
Loans Taken / (Repaid)	3,825	(1,069)	1,257	815	654
Dividend paid (incl tax)	(18,125)	(13,594)	(31,034)	(44,059)	(50,482)
Other Financing Cash Flow	29,910	(70)	12,914	13,025	6,423
Financing Cashflow	14,604	(16,024)	(18,122)	(31,540)	(44,793)
Net chg in cash	30,153	(2)	6,886	(9,013)	(1,307)
Opening cash position	211	30,364	30,362	37,248	28,235
Closing cash position	30,364	30,362	37,248	28,235	26,928

Source: Company, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 08/22/2022 11:31 AM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Key Ratios

Profitability (%)	FY21	FY22	FY23E	FY24E	FY25E
EBITDA Margin	7.6	6.5	9.3	10.7	10.9
EBIT Margin	3.3	3.3	7.0	8.5	8.8
Effective Tax Rate	18.0	17.8	20.0	20.0	20.0
Net Margin	6.0	4.3	6.6	8.1	8.3
ROCE	7.8	6.6	13.0	16.7	17.2
ROE	8.5	7.1	13.8	17.8	18.3
RoIC	22.1	35.6	73.6	86.6	90.4

Per Share Data (Rs)	FY21	FY22	FY23E	FY24E	FY25E
EPS	140.1	124.7	256.9	364.7	417.9
CEPS	240.4	217.0	346.5	461.1	522.4
BVPS	1,700.9	1,790.9	1,945.1	2,163.9	2,414.6
DPS	45.0	60.0	102.8	145.9	167.2

Valuations (x)	FY21	FY22	FY23E	FY24E	FY25E
PER	61.8	69.4	33.7	23.7	20.7
P/CEPS	36.8	40.7	25.5	19.2	16.9
P/BV	5.1	4.8	4.5	4.0	3.6
EV / Sales	3.1	2.5	1.8	1.5	1.3
EV / EBITDA	40.8	38.5	19.8	14.4	12.3
Dividend Yield (%)	0.5	0.7	1.2	1.7	1.9

Gearing Ratio (x)	FY21	FY22	FY23E	FY24E	FY25E
Net Debt/ Equity	(0.8)	(0.8)	(0.8)	(0.8)	(0.8)
Net Debt/EBIDTA	(8.1)	(7.4)	(4.2)	(3.5)	(3.5)
Working Cap Cycle (days)	(46.9)	(25.6)	(23.0)	(23.1)	(22.2)

Growth (%)	FY21	FY22	FY23E	FY24E	FY25E
Revenue	(7.0)	25.5	32.9	16.1	11.1
EBITDA	(26.8)	6.7	91.3	33.2	13.5
EBIT	(38.7)	26.0	181.4	41.7	14.8
PAT	(25.1)	(11.0)	106.0	42.0	14.6

Quarterly (Rs mn)	Q1FY22	Q2FY22	Q3FY22	Q4FY22	Q1FY23
Revenue	1,77,707	2,05,389	2,32,460	2,67,400	2,64,998
EBITDA	8,211	8,549	15,590	24,268	19,121
EBITDA Margin (%)	4.6	4.2	6.7	9.1	7.2
PAT	4,408	4,753	10,113	18,389	10,128
EPS (Rs)	14.6	15.7	33.5	60.9	33.5

Source: Company, Emkay Research

Shareholding Pattern (%)	Jun-21	Sep-21	Dec-21	Mar-22	Jun-22
Promoters	56.4	56.4	56.4	56.4	56.4
FIs	22.9	22.5	23.6	22.6	21.9
DIs	15.8	16.0	15.3	16.3	18.0
Public and Others	5.0	5.1	4.7	4.8	3.7


Source: Capitaline

RECOMMENDATION HISTORY TABLE

Date	Closing Price	TP	Period (months)	Rating	Analyst
10-Jul-22	8,476	9,650	12m	Buy	Raghunandhan NL
29-Apr-22	7,718	9,400	12m	Buy	Raghunandhan NL
06-Apr-22	7,744	9,150	12m	Buy	Raghunandhan NL
24-Feb-22	8,210	9,850	12m	Buy	Raghunandhan NL
26-Jan-22	8,603	9,850	12m	Buy	Raghunandhan NL
28-Oct-21	7,370	8,750	12m	Buy	Raghunandhan NL
02-Sep-21	6,793	8,600	12m	Buy	Raghunandhan NL
28-Jul-21	7,165	9,000	12m	Buy	Raghunandhan NL
02-Jul-21	7,574	8,500	12m	Buy	Raghunandhan NL
18-Jun-21	6,959	8,500	12m	Buy	Raghunandhan NL
01-Jun-21	7,091	8,500	12m	Buy	Raghunandhan NL
30-May-21	6,970	8,500	12m	Buy	Raghunandhan NL
28-Apr-21	6,574	8,500	12m	Buy	Raghunandhan NL
29-Jan-21	7,207	9,000	12m	Buy	Raghunandhan NL
30-Oct-20	6,965	8,216	12m	Buy	Raghunandhan NL
11-Oct-20	7,062	6,910	12m	Buy	Raghunandhan NL
28-Sep-20	6,703	6,910	12m	Buy	Raghunandhan NL
28-Aug-20	7,104	6,910	12m	Buy	Raghunandhan NL
30-Jul-20	6,265	6,910	12m	Buy	Raghunandhan NL
29-Jun-20	5,679	6,173	12m	Buy	Raghunandhan NL
14-May-20	5,114	6,173	12m	Buy	Raghunandhan NL
04-May-20	4,886	6,230	12m	Buy	Raghunandhan NL
13-Apr-20	5,283	6,230	12m	Buy	Raghunandhan NL
27-Feb-20	6,290	8,800	12m	Buy	Raghunandhan NL
09-Feb-20	6,972	8,800	12m	Buy	Raghunandhan NL
30-Jan-20	7,020	8,800	12m	Buy	Raghunandhan NL
29-Jan-20	7,010	8,800	12m	Buy	Raghunandhan NL
27-Dec-19	7,345	8,300	12m	Buy	Raghunandhan NL
18-Dec-19	7,241	8,300	12m	Buy	Raghunandhan NL
27-Nov-19	7,294	8,300	12m	Buy	Raghunandhan NL
30-Oct-19	7,557	8,300	12m	Buy	Raghunandhan NL
24-Oct-19	7,391	8,300	12m	Buy	Raghunandhan NL
23-Oct-19	7,440	8,100	12m	Buy	Raghunandhan NL
01-Oct-19	6,782	7,500	12m	Buy	Raghunandhan NL
26-Sep-19	6,857	7,500	12m	Buy	Raghunandhan NL
23-Sep-19	6,898	7,500	12m	Buy	Raghunandhan NL
12-Sep-19	6,392	5,900	12m	Hold	Raghunandhan NL
03-Sep-19	6,050	5,850	12m	Hold	Raghunandhan NL
28-Aug-19	6,103	5,850	12m	Hold	Raghunandhan NL

Source: Company, Emkay Research

RECOMMENDATION HISTORY CHART



Source: Bloomberg, Company, Emkay Research

Emkay Alpha Portfolio – Automobiles & Auto Ancillaries



Analyst: Raghunandhan NL

Contact Details

raghunandhan.nl@emkayglobal.com
+91 22 6624 2428

Sector

Automobiles and Ancillaries

Analyst bio

Raghu holds an MBA and comes with total 13 years of research experience. His team currently covers 17 stocks in the Indian Automobiles and Ancillaries space.

EAP sector portfolio

Company Name	BSE200 Weight	EAP Weight	OW/UW (%)	OW/UW (bps)	EAP Weight based on Current NAV	Change vs last published EAP (bps)
Auto & Auto Ancillaries	5.12	5.12	0%	0	100.00	
Amara Raja Batteries	0.00	0.00	NA	0	0.00	0
Apollo Tyres	0.00	0.00	NA	0	0.00	0
Ashok Leyland	0.21	0.21	0%	0	4.19	0
Atul Auto	0.00	0.00	NA	0	0.00	0
Bajaj Auto	0.53	0.40	-23%	-12	7.87	0
Bharat Forge	0.19	0.18	0%	0	3.62	0
Eicher Motors	0.43	0.43	0%	0	8.47	0
Escorts	0.00	0.02	NA	2	0.37	0
Exide Industries	0.00	0.00	NA	0	0.00	0
Hero Motocorp	0.37	0.39	4%	2	7.61	0
Mahindra & Mahindra	1.12	1.12	0%	0	21.83	0
Maruti Suzuki India	1.16	1.19	2%	2	23.19	0
Minda Industries	0.00	0.02	NA	2	0.44	0
Motherson Sumi Wiring India	0.00	0.02	NA	2	0.44	0
Samvardhana Motherson International	0.00	0.00	NA	0	0.00	0
Tata Motors	0.80	0.81	2%	1	15.83	0
Tata Motors DVR*	0.11	0.12	10%	1	2.27	0
TVS Motor	0.20	0.20	0%	0	3.88	0
Cash	0.00	0.00	NA	0	0.0	0

Source: Emkay Research

■ High Conviction/Strong Over Weight ■ High Conviction/Strong Under Weight

Sector portfolio NAV

	Base					Latest
	1-Apr-19	26-Jul-21	25-Jan-22	26-Apr-22	27-Jun-22	26-Jul-22
EAP - Auto & Auto Ancillaries	100.0	120.6	138.1	134.6	142.0	147.8
BSE200 Neutral Weighted Portfolio (ETF)	100.0	120.1	137.1	134.1	141.7	147.4

*Performance measurement base date 1st April 2019


Source: Emkay Research

Price Performance (%)

	1m	3m	6m	12m
EAP - Auto & Auto Ancillaries	4.1%	9.8%	7.0%	22.6%
BSE200 Neutral Weighted Portfolio (ETF)	4.0%	9.9%	7.5%	22.7%

Source: Emkay Research

NAV chart



Source: Emkay Research

Please see our model portfolio (Emkay Alpha Portfolio): [Nifty](#)

Please see our model portfolio (Emkay Alpha Portfolio): [SMID](#)

“Emkay Alpha Portfolio – SMID and Nifty are a supporting document to the Emkay Alpha Portfolios Report and is updated on regular intervals”

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 08/22/2022 11:31 AM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	Over 15%
HOLD	Between -5% to 15%
SELL	Below -5%

Completed Date: 28 Jul 2022 03:50:18 (SGT)

Dissemination Date: 28 Jul 2022 03:51:18 (SGT)

Sources for all charts and tables are Emkay Research unless otherwise specified.

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

- This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.
- Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

Disclaimer for U.S. persons only: This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate¹ does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of July 28, 2022
2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report
- Disclosure of previous investment recommendation produced:**
3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of July 28, 2022.
5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the July 28, 2022
6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the July 28, 2022

RESTRICTIONS ON DISTRIBUTION

General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is not for distribution into Australia.
Hong Kong	This report is not for distribution into Hong Kong.
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is not for distribution into Malaysia.
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
United Kingdom	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom. In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6 th Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India

Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com